Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study
Kenneth W. Baran, Michel Nguyen, George R. McKendall, Costas T. Lambrew, Gary Dykstra, Sebastian T. Palmeri, Raymond J. Gibbons, Steven Borzak, Burton E. Sobel, Steven G. Gourlay, Amy Chen Rundle, C. Michael Gibson, Hal V. Barron
Dive into the research topics of 'Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study'. Together they form a unique fingerprint.